florbetapir-f-18 and Myositis

florbetapir-f-18 has been researched along with Myositis* in 1 studies

Reviews

1 review(s) available for florbetapir-f-18 and Myositis

ArticleYear
Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: A systematic literature review.
    Seminars in arthritis and rheumatism, 2022, Volume: 57

    Positron emission tomography (PET), often combined with computed tomography (CT), is a well-established tool for diagnosing malignancy and inflammatory disease. The idiopathic inflammatory myopathies (IIM) are chronic, multi-system diseases characterised by skeletal muscle inflammation, the potential for extramuscular manifestations such as interstitial lung disease (ILD) and an increased risk of malignancy. We performed a systematic literature review to evaluate the utility of PET or PET-CT in evaluation of IIM.. A search of Medline and EMBASE from 1990 to 2022 using keywords related to IIM and PET was performed. English language studies of adults with IIM who had PET or PET-CT were included.. Our search identified 1173 potentially relevant abstracts, 19 of which were included. The majority of studies used [18F] fluorodeoxyglucose (FDG) PET or PET-CT scans, while the remainder used [18F] florbetapir and [. PET-CT holds promise as a single tool that can simultaneously evaluate multiple aspects of IIM. These include screening for associated malignancy, achieving an early diagnosis of ILD and evaluating muscle inflammation.

    Topics: Adult; Fluorodeoxyglucose F18; Humans; Inflammation; Myositis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography

2022